INTRODUCTION
y-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the mammalian brain. It mediates its effects via the specific interaction with the integral membrane proteins, the GABA receptors. GABA receptors can be classified according to their respective transduction mechanisms following activation, as the GABA and the GABAB receptor respectively. The focus of this review is the GABAA receptor. GABAA receptors are fastacting ligand-gated chloride ion channels. Thus receptor activation in the brain is followed within milliseconds by the gating or opening of an integral chloride ion channel which results, in general, in the hyperpolarization of the recipient neuronal cell. The GABAA receptors are of importance because of both the pivotal role that they play in the regulation of brain excitability and the fact that their function is allosterically regulated by several distinct classes of therapeutic compounds. These include anxiolytic benzodiazepines such as valium, barbiturates, neurosteroids and some volatile anaesthetics. The first GABAA receptor gene sequences were reported in 1987 by Schofield et al. [1] . Since that time, a plethora of homologous genes encoding GABAA receptor polypeptides have been identified. These polypeptides are thought to co-assemble, predominantly in the brain, to form heteromeric receptor proteins with distinct biophysical. and pharmacological properties. This review will focus on the developments in this field since the GABAA receptor genes were first cloned, addressing in particular, the structural and functional significances of mammalian GABAA receptor heterogeneity.
GABAA RECEPTOR PHARMACOLOGY
The rich pharmacology of the GABAA receptors has had a major impact in the elucidation of the biochemical properties of the GABAA receptors. Before describing the current developments in the understanding of their structures, it is necessary to have an appreciation of their pharmacological properties. Perhaps the most important of these was the realization that the anxiolytic benzodiazepine drugs (e.g. valium and librium) exerted their action by a facilitation of GABA neurotransmission (for detailed reviews, see [2, 3] ). Thus it was found that benzodiazepines bound with high affinity to an allosteric modulatory site of the GABAA receptor. In the presence of GABA, they potentiated the inhibitory response by an increase in the frequency of chloride ion channel opening. The benzodiazepine mode of action permitted the purification of the GABAA receptors by benzodiazepine affinity chromatography (e.g. [4, 5] ). Benzodiazepines such as valium, are anxiolytic. Although they are unable to activate GABAA receptors by themselves, by convention they are termed agonists. Other benzodiazepines and related compounds thought to act at similar sites within the GABAA receptors have been identified which are anxiogenic and, in the presence of GABA, decrease the frequency of chloride channel opening. These compounds are termed, by convention again, 'inverse agonists'. The benzodiazepine Ro 15-1788 has no or very low intrinsic efficacy and is recognized as an antagonist. Furthermore, although the classical benzodiazepines, valium and librium, bind to a single high-affinity site in the brain, other related compounds, which are again thought to act at the benzodiazepine or an adjacent overlapping site, show shallow displacement curves in radioligand-binding studies. It is now known that these compounds, for example the fi-carbolines, zolpidem and oxoquazepam, discriminate between GABAA receptor subtypes (see below).
Other allosteric modulators of GABAA receptors include the barbiturate drugs, non-competitive chloride channel blocking agents [including picrotoxin and the cage convulsant compound, t-butylbicyclophosphorothionate (TBPS)], certain neurosteroids, the anthelminthic agents, the avermectins, Zn2+, ethanol and the anti-convulsant drug, loreclezole. Each of these compounds modulates GABAA receptor function by binding to a distinct site within the receptor complex. Figure 1 is a diagrammatic representation of the complex pharmacology of the mammalian GABAA receptors.
MOLECULAR BIOLOGY OF GABAA RECEPTORS
At the current time, 15 mammalian GABAA receptor genes have been identified (for review see [6] ). These are classified with respect to the conservation in amino acid sequence homology of their gene products. Thus there are five GABAA receptor subunit types a, fi, y, a and p. Within four of these, isoforms exist with the now accepted nomenclature of al-a6, fll-,83, yl-y3 and pl-p2. Isoforms of a single subunit type, for example comparing all the a subunits, have at least 70 % amino acid sequence identity, whereas if the conservation in primary structure is compared across subunit classes, for example a versus , subunits, the percentage identity falls to within the range 30-40 %. Some of the GABAA receptor genes undergo alternative splicing. The most prevalent of these is the y2 subunit which exists in two forms, y2Short (y2s) and y2lOng (y2L) [7, 8] . But also, alternative splicing of the human ,B3- [9] and the rat a6-subunit gene have been described [10] . In the chick, the GABAA receptor subunit genes fl2 and f4 have been found to undergo splicing to yield ,f2' and f84' [11, 12] . (Note that for the chick, a fl4 and a y4 GABAA receptor subunit gene have been reported but it is probable that these are the avian homologues of the mammalian ,f1-and y3-subunit genes respectively, [13] .) Two invertebrate GABAA receptor genes have been cloned. They are the Drosophila Rdl gene [14] , and a GABAA receptor gene from the pond snail, Lymnaea stagnalis [15] . Interestingly, in amino acid sequence comparisons with vertebrate GABAA receptor genes, these are both most closely related to the , subunits, with identities of the order of 28 %. This low percentage of conservation is in contrast to comparisons between the subunits of various vertebrate species, where values of greater than 90 % are found. Figure 2 shows the evolutionary tree of the GABAA receptor and the related glycine receptor subunit genes reported to date. The lineage is consistent with the evolution from a single ancestral gene [16] . The mature GABAA receptor subunits have similar molecular masses as deduced from their respective cDNA sequences. These range from 48000 (y subunits) to a maximum of 64000 (a4 subunit). They all share a similar predicted domain structure not only between themselves but also with other members of the ligand-gated ion channel superfamily, most notably the prototypic peripheral nicotinic acetylcholine receptor (cf. [17] ). A schematic diagram of the pertinent features of a typical GABAA receptor subunit is shown in Figure 3 . Thus it is predicted that each subunit has an extended, extracellular, hydrophilic Nterminal domain of the order of 220 amino acids. Within this region are consensus sequences for N-glycosylation. There are four putative hydrophobic domains, M1-M4, which are predicted to span the membrane and form the chloride ion channel. M2, again by analogy with nicotinic acetylcholine receptors and also by some mutagenesis studies (see below), is thought to form the inner lining of the channel. The M I-M3 regions are adjacent to the N-terminal domain whereas M4 is at the C-terminal end of the proteins. This transmembrane topology model predicts that both the N-and C-terminal regions are extracellular but, surprisingly, this remains unproven. Separating the M3 and M4 transmembrane-spanning regions is a second hydrophilic region often referred to as the cytoplasmic or, alternatively, the intracellular loop domain. This region contains consensus sequences for phosphorylation by various protein kinases. It is also where the insertion of the eight amino acids in y2L is found.
Splicing of the /33-and x6-subunit genes yields changes in the extracellular N-terminal domain. For the /33 subunit, variant signal peptides were found [9] ; for the a6 subunit, a deletion of ten amino acids, rat numbering, a6 57-66, was discovered [10] . Figure 4 Comparison of the mammalian GABAA receptor ae-subunit primary structures
The bovine al, a2, a3 and a4 and rat a5 and a6 GABAA receptor subunit primary structures were aligned using the Multiple Sequence Alignement program of PC-GENE. Amino acids highlighted are those conserved across all the a subunits; * is amino acid sequence identity and indicates amino acid sequence similarity between all six subunits. The thick continuous lines show the positions of the transmembrane regions, M1-M4.
THE OLIGOMERIC STRUCTURES OF THE GABAA RECEPTORS It is well established by classical protein chemical methods and electron microscopy studies that the peripheral nicotinic acetylcholine receptor has a pentameric quaternary structure, a2fly'.
More recently, other members of the ligand-gated ion channel superfamily including the strychnine-sensitive glycine receptor and a cloned neuronal nicotinic acetylcholine receptor were also shown to assemble as pentamers; the glycine receptor by chemical cross-linking [19] and the neuronal nicotinic acetylcholine receptor by mixing subtypes of wild-type and mutant subunits and studying their respective channel gating properties [20] . Again by analogy, it was presumed that the GABAA receptors were also pentameric. The molecular mass of a heterogeneous population of GABAA receptors isolated from bovine cerebral cortex was determined by hydrodynamic analysis as 230000-240000 Da [21] . This, within experimental error, is consistent with the coassembly of five glycosylated GABAA receptor subunits. Furthermore, it has been shown by electron image analysis that a heterogeneous population of GABAA receptors, this time isolated from pig brain, has a rotational symmetry of 5, which is consistent again with a pentameric structure [22] . With 15 mammalian GABAA receptor genes, and not including variation due to the different splice forms of some subunits, Burt and Kamatchi [23] calculated that for pentameric structures there was the possibility of the existence of 151 887 receptors, each with a different subunit permutation. It has been a major challenge to delineate the subunit complements of native GABAA receptors to contest whether such extensive diversity is realistic. Several different approaches have been employed with the most immediate progress made utilizing the gene sequences. Thus, first the electrophysiological and pharmacological properties of cloned receptors of defined subunit composition were characterized and compared with the properties of native GABAA receptors. Secondly, the spatial and temporal distributions of the respective GABAA receptor subunit mRNAs were determined by in situ hybridization. A complementary approach was the use of GABAA receptor subunit-specific antibodies to determine subunit complements. Advances using each of these approaches are described in the following sections.
Characterization of cloned GABAA receptors
For the study of the various cloned GABAA receptors, a variety of expression systems have been employed. These include the Xenopus oocyte (e.g. [24] ), and transient (e.g. [25] ) and stable (e.g. [26] ) expression in a variety of mammalian cell types and in Sf9 insect cells using the baculovirus system (e.g. [27] ). Generally, the Xenopus oocyte system has been used for electrophysiological characterization whereas receptors expressed in the other systems are amenable to analysis by both electrophysiological and 3 [28] [29] [30] . In general, however, the a, /3, y and a subunits expressed alone assemble at low efficiency and it is probable that they do not form homo-oligomers in vivo. An exception is the p subunit. This does assemble efficiently to form a functional GABA-gated ion channel [31] . Moreover, the p homomeric channels are reminiscent of invertebrate-type GABA receptors in that they are insensitive to the classical GABAA receptor antagonist, bicuculline [32] . They are also barbiturateand benzodiazepine-insensitive [32] . The p-subunit mRNAs are found predominantly in the retina [31] . It may be that they form a subset of GABAA receptors distinct from those found in the brain; they are sometimes termed GABAC receptors.
The co-expression of a single type of a and , subunits forms robust GABA-gated ion channels which are potentiated by barbiturates and neurosteroids (e.g. [1, 33] ). But, although there are some reports that these GABA currents are modulated by benzodiazepines [1, 34] , the consensus view currently is that for a full spectrum of reproducible benzodiazepine responsiveness the co-expression of an a, and either y2 or y3 subunit is requisite [29, 35, 36] . Pairwise combinations such as ay, fly do not form channels at high efficiency. The d-subunit has not been identified so far with a particular pharmacological characteristic so it is more difficult to assess co-expression studies including this subunit. Notwithstanding this caveat, reports are consistent with the idea that co-expression of a subunit-containing paired subunit combinations do not assemble with high efficiency [37] . The co-expression of a, /3, y and a subunit has been reported to eliminate the benzodiazepine facilitation of the GABA-gated chloride ion conductance [30] , although a more recent report did observe diazepam potentiation of alflly2L, receptors [37] .
Further, single-channel properties and comparative pharmacological characterization of cells co-expressing these four subunits show that they all do co-assemble rather than forming two distinct GABAA receptor subpopulations [37] .
To summarize briefly, the results of the expression studies suggest that brain GABAA receptors comprise probably penta- [41] . There have been reports recently of the co-expression of different a subunits together with fly which suggest that the four different types of subunit are coassembling: ala3 by Verdoorn [42] and ala6 by Mathews et al. [43] . However, the benzodiazepine pharmacological profile of these GABAA receptors has not been described.
For the y subunits, the y2 and y3 polypeptides behave identically in that their presence in (a/3y) constructs is required for a full benzodiazepine agonist and inverse agonist profile [29, 35] . But in these trimeric receptors containing yl subunits, the benzodiazepine inverse agonists behave as positive facilitators [44] . Also relevant is that a recent report suggested that the y3 subunit could influence the benzodiazepine pharmacology since al,8xy3 receptors behaved as a5,8xy2 recombinants with a low affinity for zolpidem [45] .
The presence of y subunits additionally reduces the sensitivity of the cloned receptors to antagonism by Zn2+ [46, 47] . Furthermore, the presence of the y2L splice variant renders the receptors susceptible to potentiation by ethanol [48] . It is not clear whether this is a direct effect on the receptor itself or whether it occurs via a second messenger mechanism resulting in the activation of protein kinase C and subsequent phosphorylation of the y2L subunit [48] .
Until recently, it was thought that the presence of the variant of the ,B subunit did not influence the physiological or pharmacological properties of the cloned GABA A receptors.
Interestingly, Wafford et al. [49] [50] reported that a significant proportion of rat fl-subunit mRNA was non-polyadenylated, thus introducing an extra variable. Nevertheless the following generalizations and points can be made.
In adult brain, of the a-subunit mRNAs, the al is the most ubiquitously and abundantly expressed, followed by the a2 and a3 mRNAs. As stated above, the a6 mRNA is confined to the cerebellar granule cell, the a5 mRNA has a low overall distribution but is enriched particularly in the CAl and CA3 regions of the hippocampus while a4 transcripts are the rarest of the a subunits but are enriched in thalamic regions. Specific neuronal cell types have been identified which show the coexpression of at least two different a subunits; for example, the mitral cells of the olfactory bulb (al and a3) and the cerebellar granule cell (acl and a6). The a2-subunit mRNA is notably found in both neuronal cells and the Bergmann glial cells of the cerebellum. The most abundant of the ,f-subunit mRNAs are the p32 and fl3, which both show a widespread distribution; the /31 mRNA is lower. Again there are identified cell types where the different ,-subunit mRNAs co-localize, an example being once more the mitral cells of the olfactory bulb. The y2 subunit is the most abundant of the y-subunit mRNAs, followed by yl, and the y3 transcript is rare. The 8-subunit mRNA is enriched in the cerebellar granule cell and the dorsolateral and ventrolateral geniculate nuclei of the thalamus. Thus, overall, the most ubiquitously expressed subunits are the acl, a2, a3, p32, 8l3 and y2 subunits. Other isoforms show more restricted patterns of distribution. Furthermore, it is clear that some cell types express more than five different GABAA receptor subunit transcripts, thus implying more than one receptor subtype per cell. (For more detailed analyses and correlates of the in situ hybridization studies see [51] [52] [53] and for a developmental profile [54] .) THE POLYPEPTIDE COMPLEMENTS OF NATIVE GABAA RECEPTORS DETERMINED USING SUBUNIT-SPECIFIC ANTIBODIES The distributions of respective subunit mRNAs are not necessarily representative of the localizations of functional, heteromeric receptor proteins. Thus a natural progression in the determination of the subunit complements of native GABAA receptors has been the production and use of subunit-specific antibodies. [62] The antigens used for the production of such antibodies have been either synthetic peptides or bacterially derived fusion proteins, both of which correspond to the divergent regions of the various GABAA receptor subunits. In general, the peptide sequences that have been employed successfully for GABAA receptor subunit-specific antibody production are from the divergent N-terminal and C-terminal regions whereas the bacterial fusion protein antigens are larger and encompass the respective cytoplasmic loops (cf. Figure 4) . The al-a6, fl1-,f3, yl-y3 and a subunits have all been identified in brain membrane preparations by immunoblotting, by several different groups. The molecular masses of the immunoreactive polypeptides agree fairly well with the values predicted from the cDNA sequences once account is taken of potential mass contributions by Nlinked carbohydrates (summarized in [55] ). Similarly, the overall brain regional distributions and abundances of the different polypeptides determined qualitatively by immunoblotting and quantitatively by immunoprecipitation agree well with the respective GABAA subunit mRNA localizations. However, the more interesting question is which of the subunits co-assemble? Two approaches have been employed. GABAA receptor subpopulations have been purified by immunoaffinity chromatography and the co-associating subunits identified by immunoblotting. Alternatively, receptor subpopulations have been immunoprecipitated from detergent extracts of different brain regions, then the immune pellets were analysed for co-immunoprecipitated subunits. So far, most information has been forthcoming for the different a subunits of the GABAA receptors because high-affinity, specific antibodies were readily obtained. The salient features of all these studies are summarized below. [56] [57] [58] ). The most abundant of the a subunits in the adult rat brain is the al subunit [59] . The benzodiazepine pharmacology of the various GABAA receptor a-subunit-enriched receptors was similar in profile to that found for the corresponding (acx/y) cloned receptors [58] and further correlation was thus with the Type-I, Type-IT pharmacological subclasses (see above and [25] ). However, in some studies it was reported that two different a subunits could be detected in immunoaffinity-purified preparations or immune precipitates. For example, the co-existence of the al subunit with either the a2, a3, a4, a5 or a6 subunit and the a2 with the a3 subunit has been described ( [57, [60] [61] [62] [63] ; Table 2 ). GABAA receptors in detergent solution have a tendency to aggregate [21] . However, control experiments using different-specificity antibody columns in series demonstrated that the co-existence of two a-subunit variants was not artefactual. For example, purification of GABAA receptors on an a2-and an a3-subunit antibody column in series yielded purified material containing a2 and a3 but not the most abundant, al, subunit immunoreactivity [63] . Furthermore, because only two different a-subunit immunoreactivities have been reported as co-existing within a single receptor oligomer, this has formed the basis for the argument that there are probably two a subunits per receptor molecule [57, 63] . It should be stressed, however, that there is no information as yet regarding the a-subunit stoichiometry in native single a-variant GABAA receptors. The GABAA receptors containing two types of a subunit have been identified as minority subpopulations with the exception of the co-existence of the al and a6 subunits. Khan et al. [64] deduced that this population accounts for 500% of all the a6-subunit-containing GABAA receptors, which is in agreement with direct findings of Pollard et al. [65] . Although another group did not find evidence for the coexistence of al and a6 subunits this may be explained by the use of lower-avidity antibodies [66] . There have recently been reports whereby two different a subunits were co-expressed with (fly) subunits and indeed the functional properties of these were distinct from single a-subunit receptors, thus suggesting the coassembly of all four subunit types ( [42, 43] and see section on characteristic features of GABAA receptor subunit isoforms as determined by the study of recombinant receptors, above). The benzodiazepine pharmacologies of these mixed a-subunit receptors is not known. For the ala6/3y receptors, results are consistent with a 'benzodiazepine-insensitive' pharmacology, i.e. a dominance of the a6 subunit [64, 65] .
Such detailed studies have not been carried out for the /3 subunits, probably because it has been more difficult to raise useful isoform-specific antibodies. (The intracellular loops of the / subunits are more highly conserved than for the other subunit classes and, additionally, / subunits do not have a hydrophilic Cterminus.) Many studies have therefore utilized the monoclonal antibody bd-17, which recognizes both the /32 and /33 but not /31 subunits [67, 68] . Benke et al. [69] , however, recently reported the production of /31-, /32-and ,/3-subunit antibodies. In this study, it was shown that the most prevalent / subunit was /2, which was most often associated with the al subunit [69] . Moreover, quantitative immunoprecipitation studies indicated the presence of a single type of / subunit per receptor [69] . For all the GABAA receptor subpopulations that have been identified, a / subunit was also present (Table 2) . This is consistent with the identification of the / subunit as the high-affinity agonist-binding site ([70] and see below).
Of the y subunits, the y2 subunit is the most prevalent. Quirk and by analogy with the experiments carried out for the a subunits proposed the existence of two y subunits per receptor molecule. This is in agreement with two other studies. A subunit ratio of (al)2(/1)1(y2)2 was deduced in an elegant study by Backus et al. [72] by comparing the conductance properties of (acl/32y2) wild-type and mutant cloned receptors. Similarly, Khan et al. [64] deduced by immunoprecipitation studies that one subpopulation of receptors in the cerebellum comprised ala6/32/3y2Ly2S. Conflictingly, however, Togel et al. [45] and Mossier et al. [73] purified y3 and yl GABAA subunit-containing receptors respectively, but in these studies no evidence was found for the co-existence of the different y polypeptides. In the y3-subunit-enriched receptors no c5-subunit immunoreactivity was detected either, yet a low affinity for zolpidem was found ( [45] and see above).
For the a subunit, again there are inconsistencies between groups. Quirk et al. [66] found an exclusive co-localization of the a subunit with the a6 polypeptide in the cerebellum. This (c61) subunit population did not bind benzodiazepine agonists, antagonists or even inverse agonists with high affinity. No y2 immunoreactivity was detected in these cerebellar receptors. This is in contrast to the postulated co-existence of ac/y8 subunits by single-channel studies of cloned receptors (see above). Furthermore, Mertens et al. [62] found that the a subunit was more widely expressed and co-existed with al, a3, /32/3 and y2 subunits; the a6 subunit was not investigated.
It was cited earlier that Burt and Kamatchi [23] calculated a possible existence of 151 887 different GABAA receptors. A subunit stoichiometry, (a)2(/)(y)2 is the most consistent with all published work (see above and also below for further discussion). Thus, with the assumptions that within receptor oligomers, different a subunits co-exist, different /3 and y subunits do not, the a subunit substitutes for a y, and p subunits assemble as homo-oligomers, this value reduces to a more manageable 137. (It is realised that the assumptions made are inconsistent with some reports and may be an underestimation; cf. Table 2 . Nevertheless, the characterization of the native receptors has significantly reduced receptor numbers.)
THE FUNCTIONAL SIGNIFICANCES OF GABAA RECEPTOR HETEROGENEITY?
The questions which immediately arise following the discovery of the multiple receptor subtypes is, why are there so many and what distinct functions, if any, do they subserve? It can be argued that all the different GABAA receptors serve the same function in that they are all fast-acting, ligand-gated chloride ion channels and that GABAA receptor heterogeneity has evolved with the conservation of the important part of the protein, the chloride ion channel, with all other changes being redundant. The diametrically opposed view, however, is that the GABAA receptor genes have indeed evolved to serve distinct functions. [24, 74] ). These properties may be important during development where GABA acts as both a trophic agent and as a neurotransmitter (see [54] for discussion).
et al. [71] showed the co-association of the y2 and y3 subunits, Recombinant GABAA receptors also have a differential sensitivity to allosteric modulation by endogenous molecules found in the brain which include the neurosteroids and Zn2+ [33, 46, 47] . GABAA receptors which differ in their benzodiazepine pharmacological profile cannot be discussed in the context of their physiological functions since the current consensus view is that there are no endogenous benzodiazepine-like compounds. These binding sites therefore remain serendipitous for both the molecular dissection and classification of GABAA receptors and, importantly, for exploitation in the treatment of anxiety, etc.
Many of the GABAA receptor subunits contain consensus amino acid sequences for phosphorylation by protein kinase A, protein kinase C and tyrosine kinase. Some of the subunits have been shown to be phosphorylated in vitro with concomitant modulation of channel activity. Furthermore, native GABAA receptors show differential responses following activation of different protein kinases (see e.g. [75] for more detailed discussion), thus suggesting that regulation of receptor subtype activity by intracellular mechanisms may be important.
In whole-animal studies, the a6 GABAA receptor subunit has been implicated in cerebellar motor control [76] . Interestingly also, the /33-subunit gene is deleted in the neurological disorder, Angelman's syndrome [77] . The mouse pink-eyed cleft-palate (pCP) mutation has a deletion of a region which contains the at5, /33, and y3 GABAA subunit genes [78] . This deletion is homologous to the one found for Angelman's syndrome in humans and these mice show neurological dysfunction. Interestingly, however, it was recently reported that one strain had deletions which resulted in no expression of the a5-and y3-subunit genes, yet these mice were neurologically normal [79] .
LOCALIZATION OF LIGAND-BINDING DOMAINS WITHIN GABAA RECEPTORS
The initial insight into the localization of drug-binding sites within the GABAA receptors was gained from photoaffinitylabelling studies. Thus it was shown that the benzodiazepine [3H]flunitrazepam, and the high-affinity GABAA receptor agonist [3H]muscimol, photoaffinity-labelled two different GABAA receptor subunits. These were distinguished on the basis of molecular mass [80, 81] [82] . This heterogeneity was particularly evident in neonatal rat brain and furthermore showed a pharmacological specificity of photolabelling reminiscent of type-I and type-II receptors (summarized in [83] ). It is now known that this was due to the presence of the minor a-subunit isoforms. The discovery of the requirement of the y2 subunit for benzodiazepine modulation of GABA responses led to a re-evaluation of the [3H]flunitrazepam photoaffinity-labelling reaction. Using subunit-specific antibodies, it was confirmed that the al, not the y2, subunit was the site of the photoaffinity-labelling reaction [84] . Indeed, the site of labelling has been reduced to within the acl [91] . Sigel et al. [92] , however, showed that the mutation F64L in the al subunit of al/32y2 receptors resulted in a 200-fold reduction in agonist affinity. This (see above discussion), simplistically this would indicate two same residue, Phe-641, was shown to have incorporated radio- with the binding pocket for GABA at the interface of the a and ,t subunits and residues important for benzodiazepine subpharmacology at the interface between the a and y subunits. Note that in accord with the studies of Unwin [17] on the peripheral nicotinic acetylcholine receptor, the GABA binding site is depicted as approximately half-way down the extracellular region. The leucine residues (L) in the transmembrane region M2 are those conserved with the nicotinic receptor, which for that protein have been identified as the gate within the channel lumen [17] . This GABAA receptor will have type-I benzodiazepine pharmacology and, additionally, it is loreclezole-sensitive. activity following [3H]muscimol affinity labelling in the sequence TIDVF, which is unique to the al, a2, a3 and a5 subunits [93] . But note that it is unlikely that this is the major amino acid photoaffinity-labelled by [3H]muscimol since predominant labelling is associated with a 58000 Da band and although the a3 subunit has a molecular mass in this vicinity, it is not a major component ofbenzodiazepine affinity-purified GABAA receptors.
Picrotoxinin is a classical non-competitive antagonist of GABAA receptors and it has been proposed that it acts at the level of the chloride ion channel. Mutagenesis studies have identified the residues within the predicted M2 domain which are important for picrotoxin-sensitivity. Thus, a GABAA receptor subunit of a Drosophila mutant Rdl which was resistant to the insecticide dieldrin (and picrotoxin) had a single point mutation, A302S, in the putative TM2 region [94] . Furthermore, the coexpression of the glycine receptor ft subunit with the al subunit renders the glycine-gated channel picrotoxinin-insensitive [95] .
Residues within the putative TM2 domain of the subunit were subsequently identified as important for the endowment of this property [95] . More recently, Gurley et al. [96] showed directly that the mutant receptor al(fi2T246F)y2 was picrotoxin-insensitive. These reports thus suggest that the TM2 domain is important for picrotoxinin binding and they can be extrapolated as providing evidence for the M2 region forming the inner lining of the chloride ion channel.
The TM2 domain is also implicated in the binding ofloreclezole to the GABAA receptor. As described above, loreclezole sensitivity was found with ,/2-and ,f3-subunit-containing receptors [49] . Wingrove et al. [97] have further refined these studies and identified Asn-289 (p2) and Asn-290 (f3), located at the carboxyl end of TM2, as the determinant important for high-affinity loreclezole binding.
The mutagenesis studies are summarized in diagrammatic form in Figure 5 .
CONCLUSIONS
Seven years have elapsed since the first GABAA and glycine receptor gene sequences were reported. That led to the realization that there existed a ligand-gated ion channel superfamily [1] . Since then, a wealth of information has been forthcoming on the molecular and pharmacological properties of GABAA receptor genes. The major challenge now, as indeed for many of the neurotransmitter receptor proteins, is to integrate all this detail into a cohesive understanding of the functional significance of GABAA receptor heterogeneity in normal and pathological conditions. An additional future direction will include an understanding of the regulation of GABAA receptor gene expression. A developmental switch in the expression of GABAA receptor subtypes in cerebellar granule cells has recently been described [43, 98] . Further, the protein BSF 1 has been identified as a neuronal-cell-type-enriched factor involved in the differential transcription ofthe GABAA receptor 8-subunit gene [99] . Further investigation of these early reports together with the use of both GABAA receptor transgenic and knock-out mice should provide insights into function and regulation of gene expression.
